nonnucleoside reverse transcriptase inhibitor

nonnucleoside reverse transcriptase inhibitor

AIDS Any of the antiretroviral–ie, anti-HIV agents–eg, delavirdine and nevirapine which inhibit viral nonnucleoside reverse transcriptase and are combined with nucleoside RTIs to manage HIV infection. See AIDS, Antiretroviral, Reverse transcriptase inhibitor. Cf Delavirdine, Nevirapine, Protease inhibitor.
References in periodicals archive ?
Carotid artery intima-media thickness (cIMT), a signal of heart disease, increased more (got worse) over 2 years in (1) people not taking antiretroviral therapy (ART) versus those taking ART, (2) people with a viral load above 400 copies when they entered the study versus those with a viral load below 400 copies, (3) people who did not keep their viral load below 400 copies throughout the study versus those Who did and (4) people taking a protease inhibitor (PT, light cone) versus a nonnucleoside reverse transcriptase inhibitor (NNRTI, dark cone).
Bone densities were retested after 48 weeks of combination HIV therapy with a nonnucleoside reverse transcriptase inhibitor (NNRTI) and nucleoside reverse transcriptase inhibitors (NRTIs), or an NNRTI and a boosted protease inhibitor, or two NRTIs and a boosted protease inhibitor.
IQP-0410 is a novel small molecule inhibitor of HIV which primarily acts as a nonnucleoside reverse transcriptase inhibitor (NNRTI).
The importance of drug therapy is evidenced by the drop in the number of HIV deaths in the United States after the diffusion of drug therapies that include a protease inhibitor or a nonnucleoside reverse transcriptase inhibitor and at least one nucleoside reverse transcriptase inhibitor (referred hereinafter as highly active antiretroviral therapy or HAART)(Aldridge, Davis, and Doyle 2002).
CHAPTER 11 DISCOVERY AND PROCESS DEVELOPMENT OF MK-4965, A POTENT NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR
Treatment typically consists of three anti-HIV drugs, with one either a potent protease inhibitor, first available in December 1995; or a nonnucleoside reverse transcriptase inhibitor, first available in June 1996.
ZIAGEN 300mg twice daily (BID) plus lamivudine (3TC) 150mg BID plus the nonnucleoside reverse transcriptase inhibitor (NNRTI) efavirenz (EFV) 600mg once daily (QD) or 2.
BOSTON--HIV-infected patients treated with an antiretroviral regimen that included a nonnucleoside reverse transcriptase inhibitor are less likely to develop primary HIV brain pathology than are those who never received one of these agents, according to an autopsy study.
The company anticipates it will soon receive its first regulatory clearance (in the United States) to market the antiretroviral Rescriptor, a nonnucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection.
The study also found that HIV patients on a regimen of a protease inhibitor plus a nonnucleoside reverse transcriptase inhibitor had the lowest reductions in total cholesterol and triglycerides of any of the HIV patients.
John's wort should not be used with any protease inhibitor or nonnucleoside reverse transcriptase inhibitor, Dr.
Initial regimen remains a combination of two nucleoside (or nucleotide) reverse transcriptase inhibitors (nRTIs) with either a nonnucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI) with low-dose ritonavir.